There are 2789 resources available
625P - TMPRSS2-ERG expression and clinical evolution of metastatic hormone sensitive prostate cancer
Presenter: Caterina Aversa
Session: ePoster Display
626P - Estimation of overall survival with subsequent treatment effect by applying inverse probability of censoring weighting in the LATITUDE study
Presenter: Nobuaki Matsubara
Session: ePoster Display
627P - Phase II neoadjuvant trial of the anti–B7-H3 antibody, enoblituzumab, in men with localized prostate cancer: Safety, efficacy and immune correlates
Presenter: Eugene Shenderov
Session: ePoster Display
628P - Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?
Presenter: Neal Shore
Session: ePoster Display
629P - Patient-reported outcomes in prostate cancer patients receiving PSMA-targeted radionuclide therapy
Presenter: Brian Gonzalez
Session: ePoster Display
591P - A first-in-human study of FOR46 in men with metastatic castration resistant prostate cancer (mCRPC)
Presenter: Rahul Aggarwal
Session: ePoster Display
592P - Bipolar androgen therapy (BAT) plus olaparib in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Michael Schweizer
Session: ePoster Display
593P - Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Celestia Higano
Session: ePoster Display
594P - Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
Presenter: Holger Palmedo
Session: ePoster Display
595P - Correlation between genomic alterations and germline mutations in men with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Casilda Llacer Perez
Session: ePoster Display